{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genito-Urinary+Cancer&page=2", "query": { "condition": "Genito-Urinary Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genito-Urinary+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T23:06:17.185Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05902520", "title": "Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "Melanoma", "Gynecologic Cancer", "Colorectal Cancer", "Lung Cancer", "Urogenital Cancer" ], "interventions": [ { "name": "DP CD8 TIL", "type": "BIOLOGICAL" }, { "name": "DP CD8 TIL KD", "type": "BIOLOGICAL" }, { "name": "Low dose IL-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AgonOx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-06-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902520" }, { "nct_id": "NCT03134027", "title": "Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Genito Urinary Cancer", "Bladder Cancer", "Kidney Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Bone marrow biopsy", "type": "PROCEDURE" }, { "name": "Tumor biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-10-19", "completion_date": "2018-05-09", "has_results": false, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03134027" }, { "nct_id": "NCT05629065", "title": "Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Gastrointestinal Cancer", "Gynecologic Cancer", "Thoracic Cancer", "Genitourinary Cancer" ], "interventions": [ { "name": "Clinician Nudge Email", "type": "OTHER" }, { "name": "Patient Nudge Letter and Share questionaire", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2022-11-28", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05629065" }, { "nct_id": "NCT04102436", "title": "Non-Viral TCR Gene Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocrine/Neuroendocrine", "Non-Small Cell Lung Cancer", "Breast Cancer", "Gastrointestinal/Genitourinary Cancers", "Ovarian Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Sleeping Beauty Transposed PBL", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2024-03-08", "completion_date": "2024-03-08", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04102436" }, { "nct_id": "NCT07215624", "title": "Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Malignant Digestive System Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Genitourinary System Neoplasm" ], "interventions": [ { "name": "Non-Interventional Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2026-01-15", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 58, "location_summary": "Fort Smith, Arkansas • Newark, Delaware • Atlanta, Georgia + 43 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215624" }, { "nct_id": "NCT06041503", "title": "Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Bladder", "Squamous Cell Carcinoma of the Bladder", "Testicular Germ Cell Tumors" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 68, "start_date": "2026-01-20", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06041503" }, { "nct_id": "NCT04812197", "title": "Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Genito-Urinary Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection(Punch Biopsy)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-03-08", "completion_date": "2021-10-08", "has_results": false, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04812197" }, { "nct_id": "NCT03412877", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Gastrointestinal/Genitourinary Cancers", "Neuroendocrine Tumors", "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 285, "start_date": "2018-09-06", "completion_date": "2028-03-23", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412877" }, { "nct_id": "NCT04067960", "title": "Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Biliary Tract Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Malignant Brain Neoplasm", "Malignant Genitourinary System Neoplasm", "Malignant Solid Neoplasm", "Pancreatobiliary Carcinoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Pancreatic Cancer", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Pancreatic Cancer", "Stage IVB Prostate Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Genetic Testing", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 197, "start_date": "2019-06-06", "completion_date": "2022-10-06", "has_results": false, "last_update_posted_date": "2024-08-14", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04067960" }, { "nct_id": "NCT06681233", "title": "Feasibility Study of CBCT for IGRT in Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancers", "Breast Cancer", "Thoracic Cancers", "Liver Cancer", "Genito Urinary Cancer", "Gastrointestinal Cancers" ], "interventions": [ { "name": "Comparison of HyperSight CBCT imaging to conventional CBCT imaging.", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Varian, a Siemens Healthineers Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-02-19", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-06-10T23:06:17.185Z", "location_count": 4, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06681233" } ] }